Dr. Bishoy Faltas

Five teams led by Weill Cornell Medicine scientists have been awarded funding from the Starr Cancer Consortium in its 16th annual grant competition.

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells.

Three Weill Cornell Medicine faculty members have received Young Physician-Scientist Awards from the American Society for Clinical Investigation. The 2022 award recipients are Drs. Bishoy M. Faltas, Gunisha Kaur and Hasina Outtz Reed.

The Starr Cancer Consortium has awarded grant funding to three Weill Cornell Medicine-led multi-institution teams to advance their groundbreaking cancer research projects.

A significant percentage of patients with urothelial cancers have inherited gene variants that drive the progression of these cancers, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Dr. Bishoy Faltas works to develop more effective therapies for bladder cancer, a disease that’s notoriously hard to treat—and historically under-studied

A newly available drug may improve the effectiveness of immunotherapy in hard-to-treat cancers of the upper urinary tract, suggests a study published by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Findings from a recent study by a team of Weill Cornell Medicine and NewYork-Presbyterian researchers explain why a bladder cancer patient responded exceptionally well to a targeted drug when others did not. 

Seven Weill Cornell Medicine faculty members leading multi-institutional research teams were awarded grants from The Starr Foundation's 12th Starr Cancer Consortium Grant Competition to fund their innovative cancer research projects.

Dr. Bishoy Faltas, an assistant professor of medicine at Weill Cornell Medicine and an oncologist at New York Presbyterian/Weill Cornell Medical Center, has been awarded a Career Development Award from the Department of Defense to investigate the biology of a family of proteins thought to drive resistance to chemotherapy in the advanced stages of bladder cancer.